TARS vs. UTI
TARS (Tarsus Pharmaceuticals, Inc.) and UTI (Universal Technical Institute, Inc.) are both stocks. TARS operates in Biotechnology (Healthcare), while UTI operates in Education & Training Services (Consumer Defensive). Over the past 5 years, TARS returned 11.64%/yr vs 49.26%/yr for UTI. At a 0.14 correlation, their price movements are largely independent.
Performance
TARS vs. UTI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TARS achieves a -28.24% return, which is significantly lower than UTI's 70.42% return.
TARS
- 1D
- 2.35%
- 1M
- -9.00%
- YTD
- -28.24%
- 6M
- -28.24%
- 1Y
- 33.82%
- 3Y*
- 51.02%
- 5Y*
- 11.64%
- 10Y*
- —
UTI
- 1D
- 6.89%
- 1M
- 20.12%
- YTD
- 70.42%
- 6M
- 78.05%
- 1Y
- 25.79%
- 3Y*
- 89.54%
- 5Y*
- 49.26%
- 10Y*
- 30.83%
TARS vs. UTI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
TARS Tarsus Pharmaceuticals, Inc. | -28.24% | 47.88% | 173.43% | 38.13% | -34.84% | -45.56% | 100.83% |
UTI Universal Technical Institute, Inc. | 70.42% | 1.63% | 105.35% | 86.31% | -14.07% | 21.05% | 26.42% |
Correlation
The correlation between TARS and UTI is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2020 | 0.14 |
Fundamentals
TARS:
$2.52B
UTI:
$2.48B
TARS:
-$1.13
UTI:
$0.77
TARS:
4.69
UTI:
2.85
TARS:
7.23
UTI:
7.30
TARS:
$535.08M
UTI:
$868.99M
TARS:
$483.93M
UTI:
$208.88M
TARS:
-$39.55M
UTI:
$76.70M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TARS vs. UTI — Risk / Return Rank
TARS
UTI
TARS vs. UTI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Tarsus Pharmaceuticals, Inc. (TARS) and Universal Technical Institute, Inc. (UTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TARS | UTI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.30 | ||
| Sortino ratioReturn per unit of downside risk | +0.53 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.14 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 1.12 | 0.67 | +0.45 |
| Martin ratioReturn relative to average drawdown | 2.57 | 1.49 | +1.08 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TARS | UTI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.77 | 0.47 | +0.30 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.20 | 1.03 | -0.83 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.58 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.07 | +0.25 |
Drawdowns
TARS vs. UTI - Drawdown Comparison
The maximum TARS drawdown since its inception was -77.67%, smaller than the maximum UTI drawdown of -96.06%. Use the drawdown chart below to compare losses from any high point for TARS and UTI.
Loading charts...
Drawdown Indicators
| TARS | UTI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.67% | -96.06% | +18.39% |
Max Drawdown (1Y)Largest decline over 1 year | -30.42% | -38.90% | +8.48% |
Max Drawdown (3Y)Largest decline over 3 years | -47.28% | -39.36% | -7.92% |
Max Drawdown (5Y)Largest decline over 5 years | -71.29% | -51.19% | -20.10% |
Max Drawdown (10Y)Largest decline over 10 years | — | -61.88% | — |
Current DrawdownCurrent decline from peak | -28.78% | 0.00% | -28.78% |
Average DrawdownAverage peak-to-trough decline | -40.62% | -65.69% | +25.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.18% | 17.31% | -4.13% |
Volatility
TARS vs. UTI - Volatility Comparison
The current volatility for Tarsus Pharmaceuticals, Inc. (TARS) is 13.29%, while Universal Technical Institute, Inc. (UTI) has a volatility of 21.61%. This indicates that TARS experiences smaller price fluctuations and is considered to be less risky than UTI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TARS | UTI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.29% | 21.61% | -8.32% |
Volatility (6M)Calculated over the trailing 6-month period | 28.45% | 38.26% | -9.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.27% | 55.28% | -11.01% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.12% | 48.03% | +11.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.95% | 53.47% | +10.48% |
Dividends
TARS vs. UTI - Dividend Comparison
Neither TARS nor UTI has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TARS Tarsus Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
UTI Universal Technical Institute, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.69% | 5.15% |
Financials
TARS vs. UTI - Financials Comparison
This section allows you to compare key financial metrics between Tarsus Pharmaceuticals, Inc. and Universal Technical Institute, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TARS vs. UTI - Profitability Comparison
TARS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported a gross profit of 152.66M and revenue of 162.05M. Therefore, the gross margin over that period was 94.2%.
UTI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Universal Technical Institute, Inc. reported a gross profit of -109.80M and revenue of 221.40M. Therefore, the gross margin over that period was -49.6%.
TARS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported an operating income of -6.12M and revenue of 162.05M, resulting in an operating margin of -3.8%.
UTI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Universal Technical Institute, Inc. reported an operating income of 339.00K and revenue of 221.40M, resulting in an operating margin of 0.2%.
TARS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tarsus Pharmaceuticals, Inc. reported a net income of -6.97M and revenue of 162.05M, resulting in a net margin of -4.3%.
UTI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Universal Technical Institute, Inc. reported a net income of 433.00K and revenue of 221.40M, resulting in a net margin of 0.2%.
Frequently Asked Questions
TARS and UTI have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UTI has higher volatility (21.61%) compared to TARS (13.29%). In terms of maximum drawdown, TARS dropped -77.67% vs UTI's -96.06%.
TARS currently has the higher Sharpe Ratio (0.77 vs 0.47), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TARS and UTI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer